Clinical Trials
61 trialsIntraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
TOGAR
Baylor College of Medicine
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
DisTinGuish
Leap Therapeutics, Inc.
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
NeoRacing
Fudan University
nextHERIZON
Imugene Limited
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Hoffmann-La Roche
PECORINO
Ukrainian Society of Clinical Oncology
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Janssen Pharmaceutical K.K.
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
LianBio LLC
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
Laval University
LODESTAR
pharmaand GmbH
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
GASTHER2
AC Camargo Cancer Center
SOHUG
Kangbuk Samsung Hospital
repeat
Harbin Medical University
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
ExcellaBio LLC
TRAXHER2
Hoffmann-La Roche
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Novartis
LOGIC
University of Saskatchewan
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
China Medical University, China
AZD2014
Samsung Medical Center
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
CISCA
UMC Utrecht
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
Brown University
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Aduro Biotech, Inc.
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
University of California, Irvine
FluoHeart
Helsinki University Central Hospital
IPEC-GC
Centre Hospitalier Universitaire de Besancon
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer
Medical University of South Carolina
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Antineoplaston Therapy in Treating Patients With Stomach Cancer
Burzynski Research Institute
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Amgen
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
SHINE
AstraZeneca
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
University of Miami
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cornerstone Pharmaceuticals
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
European Organisation for Research and Treatment of Cancer - EORTC
A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer
Yonsei University
GC-A-003
ChineseAMS
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
University Hospitals, Leicester